Implemented an integrated analytic framework to identify therapeutic vulnerabilities in triple-negative breast cancer by combining multi-omics factor analysis with mutual information-based pathway crosstalk modeling. Mapped therapeutic vulnerabilities in triple-negative breast cancer by integrating TCGA CNV/SNV, methylome, mRNA and ncRNA profiles into a pathway-centred systems framework. MOFA and molecular interaction networks were used to identify TNBC-associated latent biology, while mutual-information and PPI-based pathway crosstalk resolved core interacting pathways. These dependencies were then translated into therapeutic hypotheses through CMap signature reversal and network-proximity drug-combination analysis, with survival associations and DepMap essentiality providing orthogonal evidence for prioritizing candidate drug combinations.
Resources: Source Code